Stifel Financial Corp Has $1.41 Million Stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Stifel Financial Corp lifted its position in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) by 41.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 189,301 shares of the company's stock after buying an additional 55,540 shares during the period. Stifel Financial Corp owned 0.30% of Treace Medical Concepts worth $1,408,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TMCI. Barclays PLC raised its stake in Treace Medical Concepts by 352.2% during the third quarter. Barclays PLC now owns 79,696 shares of the company's stock valued at $460,000 after buying an additional 62,073 shares in the last quarter. Virtu Financial LLC acquired a new stake in Treace Medical Concepts in the 3rd quarter valued at approximately $148,000. JPMorgan Chase & Co. boosted its position in Treace Medical Concepts by 215.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,262,235 shares of the company's stock worth $7,321,000 after acquiring an additional 861,689 shares during the period. Ballentine Partners LLC increased its stake in Treace Medical Concepts by 10.2% during the 4th quarter. Ballentine Partners LLC now owns 25,009 shares of the company's stock valued at $186,000 after buying an additional 2,314 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Treace Medical Concepts by 20.4% during the fourth quarter. SG Americas Securities LLC now owns 28,404 shares of the company's stock worth $211,000 after purchasing an additional 4,813 shares in the last quarter. 84.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Sean F. Scanlan sold 50,000 shares of Treace Medical Concepts stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $7.97, for a total transaction of $398,500.00. Following the completion of the sale, the insider now owns 364,081 shares in the company, valued at $2,901,725.57. The trade was a 12.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 27.72% of the stock is currently owned by corporate insiders.

Treace Medical Concepts Stock Performance

NASDAQ:TMCI traded down $0.71 during trading hours on Friday, hitting $6.83. 2,354,436 shares of the company traded hands, compared to its average volume of 667,501. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. The firm has a 50-day moving average of $7.57 and a 200 day moving average of $7.96. Treace Medical Concepts, Inc. has a twelve month low of $4.29 and a twelve month high of $10.79. The stock has a market capitalization of $429.54 million, a price-to-earnings ratio of -6.90 and a beta of 0.79.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. The firm had revenue of $52.57 million during the quarter, compared to analyst estimates of $52.07 million. Treace Medical Concepts had a negative return on equity of 51.12% and a negative net margin of 30.33%. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.30) earnings per share. On average, analysts forecast that Treace Medical Concepts, Inc. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Truist Financial decreased their target price on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating on the stock in a report on Friday, April 11th. BTIG Research raised Treace Medical Concepts from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research report on Tuesday, February 4th. Finally, UBS Group lowered their price target on Treace Medical Concepts from $10.00 to $8.60 and set a "neutral" rating for the company in a research note on Friday. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Treace Medical Concepts has a consensus rating of "Hold" and a consensus price target of $10.16.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.